Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743701 | 0.80 | CHRNB2 (0.47) | TAAR1HRH3CYP11B1 | |
| SCHEMBL30408607 | 0.80 | CHRNB2 (0.47) | TAAR1HRH3CYP11B1 | |
| SCHEMBL14308133 | 0.78 | CHRNA7 (0.56) | TAAR1HRH3CHRNA7 | |
| SCHEMBL1874677 | 0.78 | SMN1; SMN2 (0.46) | CYP11B1 | |
| SCHEMBL14308147 | 0.77 | HRH3 (0.50) | TAAR1HRH3CHRNA7 | |
| SCHEMBL20758411 | 0.76 | KDM4E (0.44) | TAAR1HRH3CYP11B1 | |
| SCHEMBL2533763 | 0.75 | CYP11B1 (0.44) | CYP11B1 | |
| SCHEMBL1873497 | 0.74 | RAB9A (0.60) | CYP11B1 | |
| SCHEMBL13430063 | 0.74 | CYP11B1 (0.41) | CYP11B1 | |
| SCHEMBL12891054 | 0.74 | CHRNA7 (0.47) | TAAR1HRH3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | TAAR1 4340/4885HRH3 2518/4885CHRNA7 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.